<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868969</url>
  </required_header>
  <id_info>
    <org_study_id>API/2017/90</org_study_id>
    <nct_id>NCT03868969</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)</brief_title>
  <acronym>FOSF'HOM</acronym>
  <official_title>Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to evaluate the clinical and microbiological efficacy of fosfomycin
      trometamol (FT) per os in the treatment of documented male urinary tract infections with
      ESBL-producing enterobacteriaceae
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with no signs of urinary tract infection</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients with no signs of urinary tract infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with persistence of clinical signs of urinary tract infection</measure>
    <time_frame>3 days</time_frame>
    <description>Number of patients with persistence of clinical signs of urinary tract infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with reoccurrence of clinical signs of urinary tract infection and positive urinary analysis</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with reoccurrence of clinical signs of urinary tract infection and positive urinary analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with digestive, cutaneous disturbance</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients with digestive, cutaneous disturbance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Fosfomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fosomycin tromethamine, one sachet for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin Oral Suspension</intervention_name>
    <description>Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days</description>
    <arm_group_label>Fosfomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical suspicion of urinary tract infection (UTI) defined by the presence of at
             least one of these signs: fever &gt; 38°C and/or sus-pubic pain and/or dysuria and/or
             pollakiuria and/or urinary burns and/or macroscopic hematuria and/or acute urinary
             retention and/or pain with the rectal examination and/or confusion

          -  And urinary analysis with leukocyturia &gt; 10 / mm3, bacteriuria &gt; 10^3 CFU/mL with ESBL
             producing enterobacteriaceae and resistance associated with fluoroquinolones (FQ) and
             cotrimoxazole (CTX) but sensitive to fosfomycin.

        Exclusion Criteria:

          -  allergy to fosfomycin and/or trometamol

          -  Presence of material in the urinary tract

          -  Severe immunosuppression

          -  Chronic prostatitis

          -  Prostate abscess

          -  Acute pyelonephritis

          -  Hemodynamic instability

          -  Chronic renal failure (clearance &lt;60 mL/min)

          -  Prior antibiotic therapy, with an antibiotic sensitive on the antibiotic
             susceptibility test except: amoxicillin - clavulanic acid, cefixime, nitrofurantoin.

          -  Co-treatment with metoclopramide
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BOUILLER</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fosfomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

